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US adults with metabolic syndrome, as defined by National
Cholesterol Education Program Adult Treatment Panel III
(NCEP ATP III) criteria, have been shown to be at increased
risk of chronic kidney disease (CKD), but there is limited
information in other populations. The relationship between
metabolic syndrome and CKD (defined as estimated
glomerular filtration rateo60 ml/min/1.73 m2) was examined
in a Southeast Asian cohort. This relationship was examined
when the subjects (n¼ 3195) were initially recruited in a
cross-sectional analysis. The risks of developing new CKD
associated with metabolic syndrome were also examined
prospectively in a subgroup (n¼ 2067) without CKD at entry
after 12 years follow-up. Metabolic syndrome was defined
according to both NCEP ATP III and the new International
Diabetes Federation (IDF) criteria. The prevalence of CKD was
1.6%, and the incidence of new CKD was 6.3%. Metabolic
syndrome by NCEP ATP III definition was associated with the
increased risk of CKD at baseline (adjusted odds ratio (OR)
2.48 and 95% confidence interval 1.33–4.62), and of
developing new CKD at follow-up (adjusted OR 1.62 and 95%
confidence interval 1.00–2.61). There was a significant graded
relationship between the number of metabolic syndrome
components present and risk of CKD. By contrast, metabolic
syndrome by IDF definition was not associated with
increased risk of CKD. These results suggest the relationship
between CKD and metabolic syndrome in a Southeast Asian
population is highly dependent on the criteria used to define
metabolic syndrome.
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Individuals with metabolic syndrome are at increased risks
for developing cardiovascular diseases, stroke, and cardio-
vascular mortality.1 Although the concept of metabolic
syndrome is widely used, several definitions of the syndrome
exist. These definitions agree on the essential components of
metabolic syndrome, but differ in the criteria used in the
classification. In 2001, the National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP III)
recommended the use of five variables such that individuals
with any three or more out of five components are classified
as having metabolic syndrome. A modified NCEP definition
with a lower cutoff threshold for waist circumference has
been recommended in Asian populations.2
More recently, the International Diabetes Federation
(IDF) has proposed a new definition of metabolic syndrome.3
The IDF definition retained four of the five NCEP ATP III
criteria, but decreased the threshold for high fasting glucose.4
In addition, the IDF definition requires the presence of
obesity using an ethnic-origin-specific threshold for waist
circumference plus any two or more of the other four
components. Although the IDF definition aims to produce a
single, universally accepted diagnostic tool to address both
clinical and research needs, more information is required
about its role in predicting clinical events in prospective
settings.
Changes in lifestyle and diet have led to an increase in
prevalence of metabolic syndrome in many parts of the world
including Asia.5 In China alone, 64 million people are
currently estimated to have metabolic syndrome.6 Globally, a
rise in the incidence of chronic kidney disease (CKD) and
end-stage renal disease in recent years paralleled increasing
prevalence of metabolic syndrome.1,7 Both cross-sectional8
and prospective9 studies of US adults have demonstrated that
individuals with metabolic syndrome are at increased risk of
CKD. However, there are sparse data on the risks of CKD
associated with the metabolic syndrome in the non-US
populations. The present report will examine the relationship
between CKD and metabolic syndrome as differently defined
by either NCEP or IDF in a specific Southeast Asian cohort.
We will examine this relationship both cross-sectionally, with
regards to the prevalence of CKD when the subjects were
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initially recruited and prospectively, with regards to the
incidence of new CKD after 12 years of follow-up.
RESULTS
Baseline characteristics
All subjects. Seventy-five subjects were on antihypertensive
therapy. No subjects were taking HMG-Co A reductase
inhibitors. Figure 1a shows the frequencies of metabolic
syndrome and the number of metabolic syndrome compo-
nents present among the 3195 subjects with complete
baseline data in 1985. Overall, 13.2% had metabolic
syndrome by NCEP ATP III criteria (METS-NCEPATP III),
19.4% had METS-NCEPMod, and 12.2% had METS-IDF,
respectively.
New CKD subgroup. In the 1997 survey, 145 subjects had
died and 301 subjects were lost to follow-up. A total of 682
subjects were excluded because they either had CKD at entry
or incomplete follow-up data. Figure 1b shows the frequen-
cies of metabolic syndrome and the numbers of metabolic
syndrome components present at entry in the 2067 subjects
with complete data included in the New CKD subgroup. In
this subgroup, 11.0% had METS-NCEPATP III, 16.9% had
METS-NCEPMod, and 10.6% had METS-IDF at baseline.
Table 1 presents the baseline characteristics of all subjects
and the New CKD subgroup by metabolic syndrome status at
entry. Subjects with METS-NCEPATP III were older, and had
higher proportion of men compared with subjects without,
in all subjects and in the New CKD subgroup.
Relationship between metabolic syndrome and the
prevalence of CKD at baseline
Among all subjects, there was 1.6% who had CKD at baseline.
Figure 2a shows the prevalence of CKD by different
definitions of the metabolic syndrome. The prevalence of
CKD was increased in subjects with METS-NCEPATP III or
METS-NCEPMod compared with subjects without (Po0.01
for each). By contrast, subjects with METS-IDF did not have
increased prevalence of CKD.
Table 2 shows odds ratios (ORs) for the prevalence of
CKD in all subjects at baseline associated with individual
component, and with different definitions of metabolic
syndrome. In the unadjusted model, high blood pressure
(BP), high triglycerides (TG), and high fasting glucose (FG)-
NCEP were associated with increased odds of CKD at
baseline. After adjustment for age, sex, and smoking status,
the prevalence of CKD at entry depended on high BP, METS-
NCEPATP III, and METS-NCEP Mod. METS-IDF was not
associated with increased risk for CKD. Figure 3a showed that
the adjusted ORs of prevalence of CKD increased with the
numbers of components of metabolic syndrome present (P
for trend o0.05 for both NCEP ATP III and NCEP Modified
definitions).
Relationship between metabolic syndrome and the incidence
of new CKD at follow-up
New CKD developed in 6.3% after 12 years. Figure 2b shows
the incidence of new CKD at follow-up by different
definitions of metabolic syndrome at entry. The incidence
of new CKD was higher in subjects with METS-NCEPATP III
or METS-NCEPMod compared with subjects without
(Po0.05 for each). By contrast, subjects with METS-IDF
did not have significantly increased incidence of new CKD.
Table 3 shows ORs for the development of new CKD
associated with individual component, and with different
definitions of metabolic syndrome. In the unadjusted model,
high TG and high FG -NCEP were associated with increased
risk for new CKD. After adjustment for age, sex, and smoking
status, the development of new CKD at follow-up was
associated with high FG-NCEP and METS-NCEPATP III.
Subjects with METS-NCEPMod had 1.3-fold increased risk of
new CKD, but this was not significant (P¼ 0.16). Subjects
with METS-IDF had no increased risk for developing new
CKD. Figure 3b showed that the adjusted ORs of new CKD
incidence increased with the numbers of components of
metabolic syndrome present at baseline (P for trend o0.05
for both NCEP ATP III and NCEP Modified definitions).
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Figure 1 | Distribution of metabolic syndrome components. The
proportion with metabolic syndrome and the number of metabolic
syndrome components at entry among (a) all subjects (n¼ 3195) and
(b) New CKD subgroup (n¼ 2067). The number of components
shown according to ATP III criteria (solid line, solid circles) or modified
criteria (dash line, open triangle). Filled columns denote frequency of
metabolic syndrome by different definitions. NCEPATP III, metabolic
syndrome by NCEP ATP III criteria; NCEPMod, NCEP modified criteria;
IDF, IDF criteria.
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The risks of CKD associated with specific combinations of
metabolic syndrome components
To further investigate which components are actually
predictive, we compared the ORs of CKD owing to all
possible combinations of three NCEP metabolic syndrome
components with subjects having zero components. The ORs
of CKD for statistically significant combinations of compo-
nents are shown in Table 4. In the prevalence study, 802 and
762 subjects had zero metabolic syndrome components by
NCEP ATP III and NCEP modified criteria, respectively.
Compared with subjects with zero factors, subjects with
selected combinations had the 8-to 12-fold higher risk of
prevalence of CKD. Although the numbers with each of these
combinations accounted for only 1–2% of the study subjects,
the OR of CKD prevalence in subjects with these combina-
tions was 1.5- to fourfolds higher than when these
components are considered individually or nearly twofold
higher than subjects with metabolic syndrome by NCEP ATP
III definition.
For the new CKD study, 547 and 524 subjects had zero
metabolic syndrome components by NCEP ATP III and
NCEP modified criteria, respectively. Subjects with high
FG-NCEPþ high BPþ high TG or subjects with high
FG-NCEPþ high TGþ obesity Asia had the highest risks of
new CKD. Subjects with these combinations had six- to
sevenfold higher odds of new CKD compared with subjects
with zero factors. Only 0.5–1.3% of the study group had these
combinations, but the risk of new CKD in these subjects were
about 2.5-fold higher than subjects with metabolic syndrome
by NCEP ATP III definition.
DISCUSSIONS
This study identified a positive relationship between meta-
bolic syndrome by NCEP ATP III definition and risk of CKD
at baseline, and such was carried also after 12 years of follow-
up in a Thai cohort. This risk is independent of confounding
factors, such as age, sex, and smoking status. By contrast,
when the IDF criteria are used, no relationship is observed
between metabolic syndrome and CKD.
Table 1 | Baseline characteristics of study subjects with or without METS-NCEPATP III
All subjects New CKD subgroup
Characteristics (N)
METS-NCEPATP III
present (424)
METS-NCEPATP III
absent (2771) P-value
METS-NCEPATP III
present (227)
METS-NCEPATP III
absent (1840) P-value
Age (years) 43.875.1 42.374.8 o0.001 43.074.8 41.774.5 o0.001
Male subjects (%) 88 78 o0.001 87 75 o0.001
Tobacco use, current (%) 47 45 NS 43 40 NS
Diabetic (%) 12 1 o0.001 9.3 1.1 o0.001
Systolic BP (mm Hg) 132.0714.4 118715.5 o0.001 130.6713.1 118.4715.2 o0.001
Diastolic BP (mm Hg) 83.979.0 73.8710.7 o0.001 83.678.4 73.7710.7 o0.001
Body mass index (kg/m2) 25.873.5 22.672.8 o0.001 25.673.3 22.572.7 o0.001
Waist circumference (cm) 88.478.7 79.378.6 o0.001 87.778.2 78.878.6 o0.001
Fasting glucose (mg/dl) 99.9733.6 88.1713.5 o0.001 97.6730.7 87.8713.2 o0.001
Total cholesterol (mg/dl) 234.8743.7 220.4741.7 o0.001 232.6743.1 220.0741.4 o0.001
LDL-c (mg/dl) 151.4741.5 145.8740.1 0.01 150.9741.2 146.3739.5 NS
HDL-c (mg/dl) 35.876.9 48.6711.3 o0.001 35.376.2 48.6711.2 o0.001
Triglycerides (mg/dl) 265.7782.6 134.7781.9 o0.001 247.77117.7 129.6774.8 o0.001
Creatinine (mg/dl) 0.9570.20 0.8870.20 o0.001 0.9270.19 0.8770.18 o0.001
eGFR (ml/min per 1.73 m2) 93.974.2 99.9724.0 o0.001 97.0724.6 100.7723.9 0.04
BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein
cholesterol; METS-NCEPATP III, metabolic syndrome by NCEP ATP III definition; NS, nonsignificant.
Continuous data are shown as mean7s.d.
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Figure 2 | Chronic kidney disease frequency and metabolic
syndrome. (a) The prevalence of CKD at entry in all subjects
(n¼ 3195) and (b) the incidence of new CKD after 12 years in the new
CKD subgroup (n¼ 2067) according to the presence (þ , dark
columns) or absence (, light columns) of metabolic syndrome. CKD,
chronic kidney disease; NCEPATP III, metabolic syndrome by NCEP ATP
III criteria; NCEPMod, metabolic syndrome by NCEP modified criteria;
IDF, metabolic syndrome by IDF criteria.
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To the best of our knowledge, this is the first analysis of
the relationship between CKD and metabolic syndrome in a
Southeast Asian cohort using a clinically meaningful end
point (estimated glomerular filtration rate (eGFR)o60 ml/
min/1.73 m2) rather than surrogate markers of renal injury,
and the first study to examine the IDF criteria of metabolic
syndrome with regards to risks of CKD. Previously, the risks
of CKD associated with metabolic syndrome as defined by
NCEP ATP III had been examined in cross-sectional studies
from the US8 and Japan,10 and in a single prospective study
from the US.9 The prevalence of CKD and incidence of new
CKD in our subjects are comparable to the US studies.8,9 The
prevalence of obesity and metabolic syndrome by both NCEP
ATP III, NCEP modified and IDF criteria observed in our
cohort are similar to Chinese6 and other Asian populations.11
This contrasts with a higher prevalence of 25–40% for
metabolic syndrome by both NCEP ATP III or IDF
definitions in the US population.8,9,12
Similar to the US studies, we found that the risk for CKD
increased with higher numbers of metabolic syndrome
components.8,9 In our subjects with metabolic syndrome by
NCEP ATP III definition, the magnitude of risk for CKD in
both cross-sectional and prospective analyses is comparable
to the US studies. The higher ORs of CKD observed in the
cross-sectional analyses compared with prospective analyses
likely reflect the fact that metabolic syndrome may not only
predispose to CKD, but also that CKD increases the
frequency of hypertension, dyslipidemia, and impaired
glucose tolerance, and hence the prevalence of metabolic
syndrome.7 When we used the modified NCEP criteria13
instead of ATP III, the numbers of persons classified as
having metabolic syndrome increased, but the magnitude of
risk for CKD tended to decrease. These findings are similar to
a study from Japan, in which subjects with metabolic
syndrome by NCEP ATP III definition had increased risk of
CKD, whereas subjects with metabolic syndrome by the
modified NCEP definition did not.10 Thus, unlike for
cardiovascular diseases, more data are needed before the
modified NCEP criteria can be applied to predict kidney
diseases in Asian subjects.
The NCEP definition gives equal weight to each metabolic
syndrome component. However, the prevalence and the
impact of each component may vary substantially between
different ethnic groups. In the US population, each
individual component of the metabolic syndrome is
associated with increased risk of CKD, albeit with different
magnitude.8,9 Experimental and epidemiologic studies that
show that hypertension and diabetes lead to CKD are well
described.14,15 In our study, when risk factors were
considered individually after adjustments for age and sex,
elevated BP was associated with increased adjusted risk of
prevalence of CKD, and elevated fasting glucose was
Table 2 | Odds ratios for the prevalence of chronic kidney disease from all study subjects (n=3195)
Variable N with variable Unadjusted 95% CI P-Value Adjusteda 95% CI P-value
High BP 1622 2.29 1.25–4.21 0.008 1.95 1.05–3.62 0.03
Low HDL-c 1075 1.56 0.89–2.74 NS 1.62 0.92–2.85 NS
High TG 1180 1.87 1.07–3.27 0.03 1.61 0.91–2.84 NS
High FG-IDF 426 1.44 0.69–2.98 NS 1.21 0.58–2.53 NS
High FG-NCEP 165 2.56 1.08–6.10 0.03 2.03 0.84–4.88 NS
Abdominal obesity-ATP III 73 0.87 0.41–6.4 NS 0.78 0.11–5.73 NS
Abdominal obesity-Asia 611 1.06 0.53–2.13 NS 0.87 0.43–4.77 NS
METS-NCEPATP III 424 2.87 1.55–5.3 0.001 2.48 1.33–4.62 0.004
METS-NCEPMod 624 2.38 1.33–4.26 0.004 2.00 1.10–3.63 0.02
METS-IDF 390 1.59 0.77–3.30 NS 1.28 0.61–2.69 NS
BP, blood pressure; CI, confidence interval; HDL-c, high-density lipoprotein cholesterol; IDF, International Diabetes Federation; METS-IDF, metabolic syndrome by IDF criteria;
METS-NCEPATP III, metabolic syndrome by NCEP ATP III criteria; MET-NCEPMod, metabolic syndrome by NCEP modified criteria; NS, nonsignificant; TG, triglycerides.
Criteria for individual component of metabolic syndrome defined in the text.
aAdjusted for age, sex, smoking status.
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Figure 3 | Risks of chronic kidney disease. The ORs adjusted for
age, sex, and smoking status of (a) CKD at baseline and (b) New CKD
after 12 years by the number of metabolic syndrome components
present at entry. Numbers of components are defined by either NCEP
ATP III (solid line, solid circles) or NCEP Modified criteria (Dash line,
open triangle).
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associated with increased risk of new CKD. Combinations of
elevated fasting glucose with other metabolic syndrome risk
factors appeared to have additive effects on the risks of CKD.
This is consistent with previous studies, which have shown
that the risk of diabetes mellitus-induced renal damage is
high in Asian subjects.16 Indeed, in Thailand, as in many
parts of Asia, diabetes has emerged as the leading cause of
end-stage renal disease.17 Several lines of evidence suggest
that dyslipidemia may be an important factor for the
development and progression of CKD.18,19 Although not
statistically significant, we also show a trend for association
with CKD for low high-density lipoprotein cholesterol
(HDL-c) and high TG with similar magnitude of adjusted
risk as the US studies.8,9
Central obesity and insulin resistance are hypothesized as
important causative factors for metabolic syndrome.1 The
importance of obesity in the development and progression of
CKD has been suggested by animal studies,7 and by the
development of focal segmental glomeruloscerosis in some
obese human subjects.20 Obesity has been shown to be a risk
factor for end-stage renal disease, but this has not been a
consistent finding.21,22 In the US population, obesity was
associated with increased prevalence of CKD.8 However, even
in the US population, the direct role of obesity as a risk factor
for new CKD might be marginal, as the confidence interval of
the adjusted OR for obesity as a risk of developing new CKD
included 1.00.9 In our study, obesity was not associated with
CKD. The number of subjects with ATP III definition of
obesity was very low compared with the US studies.8,9 Thus,
the apparent lack of effect of obesity in our study could be
ascribed to the lower number of obese subjects and the lower
degree of obesity rather than the lack of effects of obesity on
Table 3 | Odds ratios of developing new chronic kidney disease (12 years follow-up) for the New CKD subgroup (n=2067)
Variable N with variable Unadjusted 95% CI P-value Adjusteda 95% CI P-value
High BP 1012 1.38 0.94–1.91 NS 1.16 0.81–1.67 NS
Low HDL-c 683 1.19 0.82–1.71 NS 1.25 0.87–1.82 NS
High TG 695 1.47 1.02–2.10 0.04 1.26 0.88–1.82 NS
High FG-IDF 252 1.59 0.99–2.54 0.05 1.38 0.85–2.22 NS
High FG-NCEP 89 2.44 1.29–4.60 0.006 1.97 1.03–3.78 0.04
Abdominal obesity-ATP III 35 0.90 0.21–3.78 NS 0.82 0.19–3.46 NS
Abdominal obesity-Asia 361 1.44 0.94–2.20 NS 1.24 0.08–1.91 NS
METS-NCEPATP III 227 1.81 1.13–2.90 0.01 1.62 1.00–2.61 0.049
MET-NCEPMod 249 1.58 1.04–2.40 0.03 1.36 0.88–2.08 NS
METS-IDF 220 1.18 0.69–2.04 NS 0.97 0.56–1.69 NS
BP, blood pressure; CI, confidence interval; CKD, chronic kidney disease; HDL-c, high-density lipoprotein cholesterol; IDF, International Diabetes Federation; METS-IDF,
metabolic syndrome by IDF criteria; METS-NCEPATP III, metabolic syndrome by NCEP ATP III criteria; MET-NCEPMod, metabolic syndrome by NCEP modified criteria;
NS, nonsignificant; TG, triglycerides.
Criteria for individual components of metabolic syndrome defined in the text.
aAdjusted for age, sex, smoking status.
Table 4 | OR of CKD prevalence in all study subjects (n=3195) and of developing new CKD in subgroup (n=2067) associated
with different combinations of metabolic syndrome components
Prevalence components
N with
parameter OR P-value New CKD components
N with
parameter OR P-value
High FG-NCEP +high BP +high TG 61 11.9 o0.001 High FG-NCEP +high
TG +abdominal Obesity-Asia
10 7.32 0.02
High FG-NCEP +high BP +low HDL-c 41 10.5 0.007 High FG-NCEP +high BP +high TG 26 6.35 o0.001
High FG-NCEP +high BP +abdominal obesity-Asia 44 9.22 0.01
High FG-NCEP +high TG +abdominal obesity-Asia 31 8.69 0.04
High BP +low HDL-c +high TG 341 4.01 0.006
High FG-NCEP 165 5.01 NS High FG-NCEP 89 2.69 0.01
High BP 1622 2.92 0.01 High BP 1012 1.24 NS
Low HDL-c 1075 2.77 0.02 Low HDL-C 683 1.30 NS
High TG 1180 2.99 0.01 High TG 695 1.48 NS
Abdominal obesity-ATP III 73 1.84 NS Abdominal obesity-ATP III 35 1.04 NS
Abdominal obesity-Asia 611 2.10 NS Abdominal obesity-Asia 361 1.56 NS
METS-NCEPATP III 424 4.87 o0.001 METS-NCEP-ATP III 227 1.94 0.02
METS-NCEPMod 620 3.77 0.003 METS-NCEPMod 349 1.66 NS
IDF 390 2.97 0.03 IDF 220 1.34 NS
BP, blood pressure; CI, confidence interval; CKD, chronic kidney disease; HDL-c, high-density lipoprotein cholesterol; IDF, International Diabetes Federation; METS-IDF,
metabolic syndrome by IDF criteria; METS-NCEPATP III, metabolic syndrome by NCEP ATP III criteria; MET-NCEPMod, metabolic syndrome by NCEP modified criteria;
NS, nonsignificant; OR, odds ratio.
Criteria for individual components of metabolic syndrome by NCEP criteria as defined in the text. Odds ratios are derived from comparisons with subjects with zero
components as defined according to NCEP ATP III criteria except when abdominal obesity-Asia is used, when NCEP Modified criteria is used instead. Only significant
combinations of factors are shown.
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CKD development per se. Although not significant by itself,
the presence of obesity might increase the risk of CKD in the
presence of other metabolic syndrome risk factors.
By requiring the presence of obesity as an essential
component, the IDF definition attempts to increase the
specificity for the diagnosis of metabolic syndrome as a
predictor of cardiovascular diseases and reduce the possibility
of over-diagnosing subjects who happen to have a clustering
of other components in the absence of obesity.3 In the US
subjects, the prevalence of coronary heart disease is increased
in subjects with metabolic syndrome whether defined by IDF
or by NCEP ATP III.12 The relationship of metabolic
syndrome by IDF definition and CKD has not been tested.
Compared with subjects without metabolic syndrome, our
subjects with metabolic syndrome by IDF definition did not
have increased adjusted risk of CKD, although these subjects
had increased risks of cardiovascular events (W Aekplakorn,
unpublished observations). The differences in risks of CKD
observed between NCEP and IDF definitions raises impor-
tant questions about the meaning of the concept of metabolic
syndrome, specifically, whether obesity should be a pre-
requisite for the diagnosis. In addition, the risks of CKD were
higher with specific combinations of metabolic syndrome
components compared with current metabolic syndrome
definitions. Thus, the 1–2% of subjects with combinations of
elevated glucose and high TG, and high BP or subjects with
elevated glucose and high TG, and obesity by Asian criteria
consistently had the highest risks for both prevalence and
incidence of new CKD. Thus, whether the metabolic
syndrome concept provides advantages over the analysis of
specific combinations of risk factors with regard to CKD
deserves further studies.
Limitations to our study should be noted. First, in the
second survey, not all individuals who participated in the first
survey returned for follow-up. As individuals who did not
have complete data were likely to be older or have metabolic
syndrome (data not shown), exclusion of these individuals
would be expected to bias the prospective data to the null.
Second, the analyses were based mainly on the data obtained
from the first survey. The variability of the studied risk factors
was uncertain over the 12 years interval. Third, we used eGFR
rather than directly measured GFR to define CKD. This
process requires that the serum creatinine (sCr) be calibrated
by an indirect method to a US population data. The
relationship between sCr and GFR varies with race, and the
modification of diet in renal disease formula has not been
validated in a Thai population. Fourth, our population
consists mostly of middle-aged men with low prevalence of
obesity and CKD. It is possible that relative contribution of
metabolic syndrome or obesity could be different in a
population with higher proportion of women or older
subjects. Despite these limitations, both our cross-sectional
and prospective data are consistent with other published series.
Nonetheless, we cannot exclude the possibility that with larger
numbers of subjects, an effect for obesity or metabolic
syndrome according to the IDF definition would be seen.
In conclusion, the risks of CKD associated with metabolic
syndrome depend on the definition of metabolic syndrome
used. The contribution of obesity on the risk of CKD in our
population appears to be less than the US population. It is
uncertain if this relationship will change if the proportion of
subjects with obesity and metabolic syndrome increases with
continued change in diet and socioeconomic development.5
The metabolic syndrome concept is easy to apply in the
clinical settings, but it remains debatable if this offers clear
advantages over considerations of risk factors of CKD
individually or in more specific combinations in all popula-
tions. Future studies are necessary to determine if intensive
therapy in these high-risk subjects will alter the risks of CKD
or end-stage renal disease in our population or in other
populations in Asia.
MATERIALS AND METHODS
Study participants
In 1985, 7824 employees (6631 men) of the Electricity Generating
Authority of Thailand, aged 35–54 years were invited to participate
in a survey of vascular risk factors, and 3499 (2702 men and 797
women) volunteered. In 1997, the same individuals were resurveyed
using similar methods. The details had been described.23,24 The
methods are provided here in brief, as well as additional related
information.
All participants completed a self-administered questionnaire and
underwent a physical examination by trained medical personnel.
Circumferential measurements of the waist at the umbilicus were
carried out with the participant standing and rounded to the nearest
centimeter. A single BP measurement was made after 5 min rest,
using a calibrated mercury sphygmomanometer. Systolic BP and
diastolic BP were recorded as the first and fifth Korotkoff sounds,
respectively. Blood samples were drawn after 12 h overnight fast for
lipids, glucose, and creatinine. The study was approved by the
ethical committees of Electricity Generating Authority of Thailand
and Ramathibodi Hospital. Written informed consent for each
participant was obtained.
Laboratory measurements and determination of renal
function
Details of laboratory methods have previously been published.24
Lipids were measured using enzymatic calorimetric assays according
to the manufacturer’s instructions. Chylomicrons, very-low-density
lipoprotein, and low-density lipoprotein cholesterol were precipi-
tated by the addition of phosphotungstic acid and magnesium
ions.25 HDL-c, which remained in the supernatant was determined
spectroscopically after the addition of the cholesterol reagent
(Monotest cholesterol, Boehringer Mannheim, Mannheim, Ger-
many). Serum TG was determined by colorometry method from the
liberated glycerol after enzymatic hydrolysis (Peridochrom triglycer-
ides, Boehringer Mannheim, Mannheim, Germany). Low-density
lipoprotein cholesterol was calculated from the Friedewald and
Fredrickson formula.26
sCr was measured using a modified kinetic Jaffe reaction by the
same laboratory in both surveys.23,24 Coefficients of variation for
sCr were 4.96% at 1.29 mg/dl, and 5.3% at 4.0 mg/dl. Stable quality
control was maintained throughout. The medians of sCr for
participants with the same age range without hypertension or
diabetes in 1985, and the 1997 surveys showed no significant drift.
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The medians of sCrs were 1.21 mg/dl for men and 0.97 mg/dl for
women in the 1985 survey, and were 1.20 mg/dl for men and
0.91 mg/dl in 1997.
The sCr values were adjusted by a two-step process, as published
previously.23,27 First, NHANES III sCr values were calibrated to the
modification of diet in renal disease laboratory, requiring a
correction factor of 0.23 mg/dl.28 The mean sCr values for each
gender and age group from our study were then aligned with
corrected mean sCr of the corresponding group from the NHANES
III study.29 The adjusted sCr was then used to determine the eGFR
according to the abbreviated modification of diet in renal disease
formula as follows:28
eGFR ðml=min per 1:73m2Þ ¼186:3sCr1:154Age0:203
ð0:742 for womenÞ
Definitions
CKD is defined as eGFR o60ml=min=1:73m2 28 Diabetes is defined
as a fasting glucose above 126 mg/dl or a reported history of diabetes
mellitus. Metabolic syndrome is defined using the following criteria.
NCEP ATP III (METS-NCEPATP III) includes individuals with
three or more of the following five components:30 (1) abdominal
obesity-ATP III (waist circumference 4102 cm for men, or 488 cm
for women); (2) high TG(X150 mg/dl); (3) low HDL-c (men
o40 mg/dl or women o50 mg/dl); and (4) High BP (systolic BP
X130 or diastolic BPX85 mm Hg or treatment of hypertension);
and (5) High fasting glucose NCEP (FG X110 mg/dl). NCEP
modified (METS-NCEPMod) uses a modified abdominal girth cutoff
to define abdominal obesity-Asia (waist circumferences 490 cm for
men, or 480 cm for women).13 IDF (METS-IDF) requires the
presence of abdominal obesity according to ethnic-specific cutoff
waist circumference3 (waist circumferences 490 cm for men, or
480 cm for women, which is identical to the criteria used in
NCEPMod) plus any two or more of the following: (1) high TG (TG
X150 mg/dl or treatment for this abnormality), (2) low HDL-c
(HDL-c o40 mg/dl in male subjects and o50 mg/dl in female
subjects or treatment for this abnormality), (3) high BP (systolic
BPX130 or diastolic BPX85 mm Hg or treatment of hypertension),
(4) high fasting glucose-IDF (FG X100 mg/dl or previously
diagnosed type II diabetes).
Outcome measures
Only participants with complete baseline data for sCr and all
metabolic syndrome components are included for analysis. Two
outcome measures are investigated. The first is the prevalence of
CKD among the subjects at baseline. The second is the incidence of
new CKD after 12 years follow-up. The latter is determined from the
New CKD subgroup defined as subjects with no CKD at entry, but
developed CKD at follow-up. Participants who do not have sCr
results in 1997, are lost to follow up, or died are excluded from this
subgroup.
Statistical analyses
The frequency of METS-NCEP and METS-IDF and its individual
components as well as the number of metabolic syndrome
components present (i.e. 0, 1, 2, 3, 4, 5) were determined. Mean
values of continuous variables and percentages of categorical
variables for exposures, covariates, and outcomes were calculated
by metabolic syndrome status. The prevalence of CKD and
incidence of new CKD were determined for subjects according to
the metabolic syndrome status.
ORs of CKD, unadjusted and adjusted for age, sex, and smoking
status, were calculated using logistic regression models for
individual components of the metabolic syndrome, and for the
presence of metabolic syndrome. We compared subjects with 1, 2, 3,
4, or 5 components with subjects having zero components. The 4
and 5 components were combined to avoid low numbers. ORs of
CKD due to individual and all possible combinations of three NCEP
metabolic syndrome factors were also compared with subjects
having zero components to identify combinations with highest risk.
Zero component was defined according to NCEP ATP III definition
except for when obesity-Asia is used, when zero component was
defined according to NCEP Mod.
All statistical analyses were performed using SPSS software (SPSS
Version 10; SPSS Inc, Chicago, IL). Continuous data are reported as
mean7s.d. Po0.05 is considered statistically significant.
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